ExPASy logo ExPASy Home page Site Map Search ExPASy Contact us Swiss-Prot
Notice: This page will be replaced with www.uniprot.org. Please send us your feedback!
Search for

UniProtKB/Swiss-Prot entry P00813


[Entry info] [Name and origin] [References] [Comments] [Cross-references] [Keywords] [Features] [Sequence] [Tools]

Note: most headings are clickable, even if they don't appear as links. They link to the user manual or other documents.
Entry information
Entry name ADA_HUMAN
Primary accession number P00813
Secondary accession numbers Q53F92 Q6LA59
Integrated into Swiss-Prot on July 21, 1986
Sequence was last modified on January 23, 2007 (Sequence version 3)
Annotations were last modified on    November 4, 2008 (Entry version 113)
Name and origin of the protein
Protein name Adenosine deaminase
Synonyms EC 3.5.4.4
Adenosine aminohydrolase
Gene name
Name: ADA
From
Homo sapiens (Human) [TaxID: 9606] 
Taxonomy Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo.
Protein existence 1: Evidence at protein level;
References
[1]
NUCLEOTIDE SEQUENCE [MRNA].
PubMed=6090454 [NCBI, ExPASy, EBI, Israel, Japan]
Daddona P.E., Shewach D.S., Kelley W.N., Argos P., Markham A.F., Orkin S.H.;
"Human adenosine deaminase. cDNA and complete primary amino acid sequence.";
J. Biol. Chem. 259:12101-12106(1984).
[2]
NUCLEOTIDE SEQUENCE [MRNA].
DOI=10.1093/nar/12.5.2439; PubMed=6546794 [NCBI, ExPASy, EBI, Israel, Japan]
Wiginton D.A., Adrian G.S., Hutton J.J.;
"Sequence of human adenosine deaminase cDNA including the coding region and a small intron.";
Nucleic Acids Res. 12:2439-2446(1984).
[3]
NUCLEOTIDE SEQUENCE [GENOMIC DNA].
PubMed=3839456 [NCBI, ExPASy, EBI, Israel, Japan]
Valerio D., Duyvesteyn M.G.C., Dekker B.M.M., Weeda G., Berkvens T.M., van der Voorn L., van Ormondt H., van der Eb A.J.;
"Adenosine deaminase: characterization and expression of a gene with a remarkable promoter.";
EMBO J. 4:437-443(1985).
[4]
NUCLEOTIDE SEQUENCE [GENOMIC DNA].
DOI=10.1021/bi00373a017; PubMed=3028473 [NCBI, ExPASy, EBI, Israel, Japan]
Wiginton D.A., Kaplan D.J., States J.C., Akeson A.L., Perme C.M., Bilyk I.J., Vaughn A.J., Lattier D.L., Hutton J.J.;
"Complete sequence and structure of the gene for human adenosine deaminase.";
Biochemistry 25:8234-8244(1986).
[5]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
TISSUE=Thymus;
Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.;
Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
[6]
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
DOI=10.1038/414865a; PubMed=11780052 [NCBI, ExPASy, EBI, Israel, Japan]
Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R., Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L., Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P., Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E., Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J., Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D., Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S., Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D., Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A., Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T., Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I., Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.;
"The DNA sequence and comparative analysis of human chromosome 20.";
Nature 414:865-871(2001).
[7]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
TISSUE=Brain, and Placenta;
DOI=10.1101/gr.2596504; PubMed=15489334 [NCBI, ExPASy, EBI, Israel, Japan]
The MGC Project Team;
"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).";
Genome Res. 14:2121-2127(2004).
[8]
PROTEIN SEQUENCE OF 2-11, ACETYLATION AT ALA-2, AND MASS SPECTROMETRY.
TISSUE=B-cell lymphoma;
Bienvenut W.V.;
Submitted (AUG-2004) to UniProtKB.
[9]
NUCLEOTIDE SEQUENCE [MRNA] OF 141-363.
PubMed=6688808 [NCBI, ExPASy, EBI, Israel, Japan]
Orkin S.H., Daddona P.E., Shewach D.S., Markham A.F., Bruns G.A., Goff S.C., Kelley W.N.;
"Molecular cloning of human adenosine deaminase gene sequences.";
J. Biol. Chem. 258:12753-12756(1983).
[10]
VARIANT ADA*2 ASN-8.
DOI=10.1111/j.1469-1809.1994.tb00720.x; PubMed=8031011 [NCBI, ExPASy, EBI, Israel, Japan]
Hirschhorn R., Yang D.R., Israni A.;
"An Asp8Asn substitution results in the adenosine deaminase (ADA) genetic polymorphism (ADA 2 allozyme): occurrence on different chromosomal backgrounds and apparent intragenic crossover.";
Ann. Hum. Genet. 58:1-9(1994).
[11]
VARIANTS ADASCID.
PubMed=6208479 [NCBI, ExPASy, EBI, Israel, Japan]
Adrian G.S., Wiginton D.A., Hutton J.;
"Structure of adenosine deaminase mRNAs from normal and adenosine deaminase-deficient human cell lines.";
Mol. Cell. Biol. 4:1712-1717(1984).
[12]
VARIANT ADASCID GLN-101.
PubMed=3839802 [NCBI, ExPASy, EBI, Israel, Japan]
Bonthron D.T., Markham A.F., Ginsburg D., Orkin S.H.;
"Identification of a point mutation in the adenosine deaminase gene responsible for immunodeficiency.";
J. Clin. Invest. 76:894-897(1985).
[13]
VARIANTS ADASCID TRP-101; HIS-211 AND VAL-329.
PubMed=3182793 [NCBI, ExPASy, EBI, Israel, Japan]
Akeson A.L., Wiginton D.A., Dusing M.R., States J.C., Hutton J.J.;
"Mutant human adenosine deaminase alleles and their expression by transfection into fibroblasts.";
J. Biol. Chem. 263:16291-16296(1988).
[14]
VARIANT ADASCID GLN-297.
PubMed=2783588 [NCBI, ExPASy, EBI, Israel, Japan]
Hirschhorn R., Tzall S., Ellenbogen A., Orkin S.H.;
"Identification of a point mutation resulting in a heat-labile adenosine deaminase (ADA) in two unrelated children with partial ADA deficiency.";
J. Clin. Invest. 83:497-501(1989).
[15]
VARIANTS ADASCID CYS-156 AND LEU-291.
DOI=10.1002/humu.1380010214; PubMed=1284479 [NCBI, ExPASy, EBI, Israel, Japan]
Hirschhorn R.;
"Identification of two new missense mutations (R156C and S291L) in two ADA-SCID patients unusual for response to therapy with partial exchange transfusions.";
Hum. Mutat. 1:166-168(1992).
[16]
VARIANTS ADASCID LEU-101; HIS-156 AND MET-177.
PubMed=8227344 [NCBI, ExPASy, EBI, Israel, Japan]
Santisteban I., Arredondo-Vega F.X., Kelly S., Mary A., Fischer A., Hummell D.S., Lawton A., Sorensen R.U., Stiehm E.R., Uribe L., Weinberg K., Hershfield M.S.;
"Novel splicing, missense, and deletion mutations in seven adenosine deaminase-deficient patients with late/delayed onset of combined immunodeficiency disease. Contribution of genotype to phenotype.";
J. Clin. Invest. 92:2291-2302(1993).
[17]
VARIANT ADASCID ARG-20.
DOI=10.1006/clin.1994.1026; PubMed=8299233 [NCBI, ExPASy, EBI, Israel, Japan]
Yang D.R., Huie M.L., Hirschhorn R.;
"Homozygosity for a missense mutation (G20R) associated with neonatal onset adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID).";
Clin. Immunol. Immunopathol. 70:171-175(1994).
[18]
VARIANT ADASCID GLN-142, AND VARIANT ARG-80.
DOI=10.1093/hmg/4.11.2081; PubMed=8589684 [NCBI, ExPASy, EBI, Israel, Japan]
Santisteban I., Arredondo-Vega F.X., Kelly S., Loubser M., Meydan N., Roifman C., Howell P.L., Bowen T., Weinberg K.I., Schroeder M.L., Hershfield M.S.;
"Three new adenosine deaminase mutations that define a splicing enhancer and cause severe and partial phenotypes: implications for evolution of a CpG hotspot and expression of a transduced ADA cDNA.";
Hum. Mol. Genet. 4:2081-2087(1995).
[19]
VARIANTS ADASCID ASP-15; ASP-83 AND ASP-179.
DOI=10.1002/humu.1380050309; PubMed=7599635 [NCBI, ExPASy, EBI, Israel, Japan]
Santisteban I., Arredondo-Vega F.X., Kelly S., Debre M., Fisher A., Perignon J.L., Hilman B., Eldahr J., Dreyfus D.H., Gelfand E.W., Howell P.L., Hershfield M.S.;
"Four new adenosine deaminase mutations, altering a zinc-binding histidine, two conserved alanines, and a 5' splice site.";
Hum. Mutat. 5:243-250(1995).
[20]
VARIANTS ADASCID MET-152 AND ILE-233.
DOI=10.1007/s004390050460; PubMed=9225964 [NCBI, ExPASy, EBI, Israel, Japan]
Hirschhorn R., Borkowsky W., Jiang C.-K., Yang D.R., Jenkins T.;
"Two newly identified mutations (Thr233Ile and Leu152Met) in partially adenosine deaminase-deficient (ADA-) individuals that result in differing biochemical and metabolic phenotypes.";
Hum. Genet. 100:22-29(1997).
[21]
VARIANTS ADASCID CYS-74; MET-129; GLU-140; TRP-149 AND PRO-199.
Arredondo-Vega F.X., Santisteban I., Notarangelo L.D., el Dahr J., Buckley R., Roifman C., Conley M.E., Hershfield M.S.;
"Seven novel mutations in the adenosine deaminase (ADA)gene in patients with severe and delayed onset combined immunodeficiency: G74C, V129M, G140E, R149W, Q199P, 462delG, and E337del.";
Hum. Mutat. 11:482-482(1998).
[22]
EFFECT OF VARIANT ADA*2 ASN-8 ON SLEEP.
DOI=10.1073/pnas.0505414102; PubMed=16221767 [NCBI, ExPASy, EBI, Israel, Japan]
Retey J.V., Adam M., Honegger E., Khatami R., Luhmann U.F.O., Jung H.H., Berger W., Landolt H.-P.;
"A functional genetic variation of adenosine deaminase affects the duration and intensity of deep sleep in humans.";
Proc. Natl. Acad. Sci. U.S.A. 102:15676-15681(2005).
Comments
  • CATALYTIC ACTIVITY: Adenosine + H2O = inosine + NH3.
  • TISSUE SPECIFICITY: Found in all tissues, occurs in large amounts in T-lymphocytes and, at the time of weaning, in gastrointestinal tissues.
  • POLYMORPHISM: There is a common allele, ADA*2, also known as the ADA 2 allozyme. It is associated with the reduced metabolism of adenosine to inosine. It specifically enhances deep sleep and slow-wave activity (SWA) during sleep.
  • DISEASE: Defects in ADA are the cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-negative/NK-cell-negative due to adenosine deaminase deficiency (ADASCID) [MIM:102700]. SCID refers to a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients with SCID present in infancy with recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development. ADA-SCID is an autosomal recessive form accounting for about 50% of non-X-linked SCIDs. ADA deficiency has been diagnosed in chronically ill teenagers and adults (late or adult onset). Population and newborn screening programs have also identified several healthy individuals with normal immunity who have partial ADA deficiency.
  • DISEASE: In hereditary hemolytic anemia, the level of this enzyme in erythrocytes increases 50-70 times.
  • SIMILARITY: Belongs to the adenosine and AMP deaminases family.
  • WEB RESOURCE: Name=ADAbase; Note=ADA mutation db; URL="http://bioinf.uta.fi/ADAbase/";.
  • WEB RESOURCE: Name=GeneReviews; URL="http://www.genetests.org/query?gene=ADA";.
  • WEB RESOURCE: Name=Wikipedia; Note=Adenosine deaminase entry; URL="http://en.wikipedia.org/wiki/Adenosine_deaminase";.
Copyright
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms. Distributed under the Creative Commons Attribution-NoDerivs License.
Cross-references
Sequence databases
EMBL
X02994; CAA26734.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
X02189; CAA26130.1; ALT_SEQ; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
X02190; CAA26130.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
X02191; CAA26130.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
X02192; CAA26130.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
X02193; CAA26130.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
X02194; CAA26130.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
X02195; CAA26130.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
X02196; CAA26130.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
X02197; CAA26130.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
X02198; CAA26130.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
X02199; CAA26130.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
M13792; AAA78791.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AL139352; CAH73885.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
Z97053; CAH73885.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
Z97053; CAB09782.2; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AL139352; CAB09782.2; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AK223397; BAD97117.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
BC007678; AAH07678.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
BC040226; AAH40226.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
PIR A91032; DUHUA.
RefSeq NP_000013.2; -.
UniGene Hs.654536
3D structure databases
PDB
1M7M; Model; -; A=1-363.[ExPASy / RCSB / EBI]
PDBsum 1M7M; -.
SMR P00813; 3-350, 4-351.
ModBase P00813.
Protein-protein interaction databases
DIP DIP:371N; -.
Enzyme and pathway databases
Reactome REACT_1698; Nucleotide metabolism.
2D gel databases
Aarhus/Ghent-2DPAGE 5305; IEF.
Organism-specific databases
H-InvDB HIX0015842; -.
HGNC HGNC:186; ADA.
GenAtlas ADA.
HPA CAB004307; -.
HPA001399; -.
MIM 102700; phenotype. [NCBI / EBI]
608958; gene. [NCBI / EBI]
Orphanet 277; Severe combined immunodeficiency due to adenosine deaminase deficiency.
PharmGKB PA24503; -.
GeneCards P00813.
Gene expression databases
ArrayExpress P00813; -.
CleanEx HS_ADA; -.
GermOnline ENSG00000196839; Homo sapiens.
Ontologies
GO
GO:0005829; Cellular component: cytosol (inferred from experiment from Reactome).
GO:0009897; Cellular component: external side of plasma membrane (inferred from direct assay from UniProtKB).
GO:0005764; Cellular component: lysosome (inferred from direct assay from UniProtKB).
GO:0004000; Molecular function: adenosine deaminase activity (inferred from direct assay from UniProtKB).
GO:0005515; Molecular function: protein binding (inferred from physical interaction from UniProtKB).
GO:0008270; Molecular function: zinc ion binding (inferred from mutant phenotype from UniProtKB).
GO:0006154; Biological process: adenosine catabolic process (inferred from direct assay from UniProtKB).
GO:0046103; Biological process: inosine biosynthetic process (inferred from direct assay from MGI).
GO:0060169; Biological process: negative regulation of adenosine receptor signaling pathway (inferred from direct assay from UniProtKB).
GO:0032261; Biological process: purine nucleotide salvage (inferred from mutant phenotype from UniProtKB).
GO:0033632; Biological process: regulation of cell-cell adhesion mediated by integrin (inferred from direct assay from UniProtKB).
GO:0001666; Biological process: response to hypoxia (inferred from direct assay from UniProtKB).
GO:0042110; Biological process: T cell activation (inferred from direct assay from UniProtKB).
QuickGo view.
Family and domain databases
InterPro IPR006650; A/AMP_deam_AS.
IPR001365; A/AMP_deaminase.
IPR006330; A_deaminase.
Graphical view of domain structure.
PANTHER PTHR11409; A/AMP_deaminase; 1.
Pfam PF00962; A_deaminase; 1.
Pfam graphical view of domain structure.
TIGRFAMs TIGR01430; aden_deam; 1.
PROSITE PS00485; A_DEAMINASE; 1.
BLOCKS P00813.
ProtoNet P00813.
Proteomic databases
PeptideAtlas P00813; -.
Genome annotation databases
Ensembl ENSG00000196839; Homo sapiens. [Contig view]
GeneID 100; -.
KEGG hsa:100; -.
Phylogenomic databases
HOGENOM P00813; -.
HOVERGEN P00813; -.
Other
DrugBank DB00640; Adenosine.
DB00242; Cladribine.
DB00975; Dipyridamole.
DB00199; Erythromycin.
DB01073; Fludarabine.
DB00249; Idoxuridine.
DB01280; Nelarabine.
DB00552; Pentostatin.
DB00277; Theophylline.
DB00194; Vidarabine.
NextBio 377; -.
SOURCE ADA; Homo sapiens.
UniRef View cluster of proteins with at least 50% / 90% / 100% identity.
Keywords
3D-structure; Acetylation; Direct protein sequencing; Disease mutation; Hereditary hemolytic anemia; Hydrolase; Nucleotide metabolism; Polymorphism; SCID.
Features
SEVIEWER logo Feature table viewer
KeyFrom   To Length Description FTId
INIT_MET   1     1        Removed. 
CHAIN   2   363  362     Adenosine deaminase. PRO_0000194352
ACT_SITE   214   214        Potential. 
ACT_SITE   262   262        Potential. 
ACT_SITE   295   295        Potential. 
ACT_SITE   296   296        Potential. 
MOD_RES   2     2        N-acetylalanine. 
VARIANT   8     8  1     D -> N (in allele ADA*2; in about 10% of the population; 20% to 30% decrease in activity; affects duration and intensity of deep sleep). VAR_002209 [3D]
VARIANT   15    15  1     H -> D (in ADASCID; loss of activity). VAR_002210 [3D]
VARIANT   20    20  1     G -> R (in ADASCID; loss of activity). VAR_002211 [3D]
VARIANT   74    74  1     G -> C (in ADASCID; delayed-onset). VAR_002212 [3D]
VARIANT   76    76  1     R -> W (in ADASCID). VAR_002213 [3D]
VARIANT   80    80  1     K -> R. VAR_002214 [3D]
VARIANT   83    83  1     A -> D (in ADASCID; loss of activity). VAR_002215 [3D]
VARIANT   101   101  1     R -> L (in ADASCID). VAR_002216 [3D]
VARIANT   101   101  1     R -> Q (in ADASCID; loss of activity). VAR_002218 [3D]
VARIANT   101   101  1     R -> W (in ADASCID). VAR_002217 [3D]
VARIANT   107   107  1     L -> P (in ADASCID). VAR_002219 [3D]
VARIANT   129   129  1     V -> M (in ADASCID; delayed-onset). VAR_002220 [3D]
VARIANT   140   140  1     G -> E (in ADASCID). VAR_002221 [3D]
VARIANT   142   142  1     R -> Q (in ADASCID; 20% of activity; ADA deficiency of late onset). VAR_002222 [3D]
VARIANT   149   149  1     R -> Q (in ADASCID). VAR_002223 [3D]
VARIANT   149   149  1     R -> W (in ADASCID). VAR_002224 [3D]
VARIANT   152   152  1     L -> M (in ADASCID; 1,5% of activity, partial ADA deficiency). VAR_002225 [3D]
VARIANT   156   156  1     R -> C (in ADASCID). VAR_002226 [3D]
VARIANT   156   156  1     R -> H (in ADASCID). VAR_002227 [3D]
VARIANT   177   177  1     V -> M (in ADASCID; loss of activity). VAR_002228 [3D]
VARIANT   179   179  1     A -> D (in ADASCID; loss of activity). VAR_002229 [3D]
VARIANT   199   199  1     Q -> P (in ADASCID; delayed-onset). VAR_002230 [3D]
VARIANT   211   211  1     R -> C (in ADASCID; late onset). VAR_002231 [3D]
VARIANT   211   211  1     R -> H (in ADASCID). VAR_002232 [3D]
VARIANT   215   215  1     A -> T (in ADASCID). VAR_002233 [3D]
VARIANT   216   216  1     G -> R (in ADASCID; severe). VAR_002234 [3D]
VARIANT   233   233  1     T -> I (in ADASCID; 20% of activity, partial ADA deficiency). VAR_002235 [3D]
VARIANT   274   274  1     P -> L (in ADASCID). VAR_002236 [3D]
VARIANT   291   291  1     S -> L (in ADASCID). VAR_002237 [3D]
VARIANT   297   297  1     P -> Q (in ADASCID). VAR_002238 [3D]
VARIANT   304   304  1     L -> R (in ADASCID; loss of activity). VAR_002239 [3D]
VARIANT   329   329  1     A -> V (in ADASCID). VAR_002240 [3D]
VARIANT   337   337  1     Missing (in ADASCID). VAR_002241
CONFLICT   340   340        K -> R (in Ref. 5; BAD97117). 
STRAND   10    17  8      
HELIX   23    33  11      
HELIX   42    49  8      
HELIX   57    61  5      
HELIX   64    71  8      
HELIX   75    92  18      
STRAND   94   101  8      
HELIX   103   106  4      
HELIX   125   143  19      
STRAND   146   154  9      
HELIX   161   170  10      
TURN   173   175  3      
STRAND   176   183  8      
HELIX   190   192  3      
HELIX   194   206  13      
STRAND   209   218  10      
HELIX   220   228